TVM Capital

Life Sciences

The TVM Capital Life Science Practice is one of the global leaders in the financing of life sciences growth companies. Next to our headquarters in Munich, we have an established office in Boston, where we have invested in exciting technology companies for almost 20 years. More recently we have created market presence in the Middle East and have established ourselves through Venture Partners in New York and Singapore.

We believe that a global reach, and access to regional growth opportunities and businesses on a global basis is going to be key for successful investing in our target industry. This applies to business and corporate development activities of our portfolio companies as well as to direct investments in the sector. We build on the expertise, experience, international approach and demonstrated success in our more than 100 previous investments and almost 40 IPOs in biotechnology and pharmaceuticals.

Our team is comprised of deal partners and an advisory group of venture partners and senior advisors that combine investment experience with their pharmaceutical and biotech operating track record from companies like Aventis, Boehringer Ingelheim, Boehringer Mannheim, GSK, Hoechst, Hoffman-La Roche, AstraZeneca, McKinsey & Company, and BASF Pharma.

The TVM Capital Life Sciences Practice is a provider of venture and growth capital to the international biopharmaceutical industry.

We help entrepreneurs conceptualize and launch technology-based companies with seed and early stage funding, we develop single drug assets with our industry specialists, and we also provide growth capital to private or public companies in their commercialization phase by financing market introductions, a broadening of their product portfolio, acquisitions or international expansion.

The TVM Capital Life Sciences Team brings extensive networks and knowledge regarding science, product evaluation and development, manufacturing as well as commercialization strategies.

The team believes a portfolio company must capitalize on the major sources of growth in these industries — true product innovation, new and fast emerging markets, and strategic mergers and acquisitions. Our experience in traditional early and late-stage venture, growth venture, growth capital, and small to mid-size private equity makes us a unique partner in these efforts.

Of particular interest to us are:

Small and mid-sized revenue-stage companies in need of restructuring, roll-ups, and strategic M&A
Opportunities to create new growth companies through in-licensing or acquisition as a result of pharmaceutical industry strategy or restarts and funding gaps in biotechnology
Growth companies with efforts to bridge into other major world markets like the US or into fast emerging new markets like India and China
Development stage and revenue stage biotechnology companies in Europe, the U.S. and Asia.